Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance olaparib vs placebo in platinum-sensitive advanced non-small cell lung cancer
2014-005586-75Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Olaparib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Oct 2015; status: active.
02
Drugs
olaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-005586-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005586-75.